Grace Therapeutics announced that the FDA issued a Complete Response Letter rejecting its New Drug Application for GTx-104, citing issues with product packaging, toxicology assessments, and manufacturing. Following this, the company's stock price plunged 45.48% to $2.35 per share. Pomerantz LLP is investigating whether Grace and its executives engaged in securities fraud or unlawful business practices related to this matter. Investors affected are encouraged to contact the law firm for potential class action participation.
Metalla Royalty & Streaming Ltd. has nominated Sandeep Singh to its board of directors for election at the upcoming annual general meeting on June 23, 2026. Singh brings 20 years of experience in mining, royalties, and capital markets, currently serv...
MicroAlgo announced a new multi-objective evolutionary algorithm that automates quantum circuit design, optimizing metrics like accuracy, depth, and gate usage for resource-limited quantum hardware. Tested with Quantum Fourier Transform and Grover's ...
Old Republic International Corporation declared a quarterly dividend of 31.5 cents per share, payable June 15, 2026, to shareholders of record on June 5. This marks the 45th consecutive year the company has increased its regular dividend and the 85th...
A U.S. District Court has dismissed the Federal Trade Commission's (FTC) accusations against Cliq, a financial technology company, clearing it of fraud after a three-year investigation. The court rejected the FTC's demands for harsh penalties, includ...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group plc, disclosed its trading activity on May 14, 2026. The bank purchased and sold 82,500 ordinary shares of the company at prices ranging from approximately 249....
